Analyst Reco. AbCellera Biologics Inc.

Equities

ABCL

CA00288U1066

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
3.86 ^USD	+0.26%		+4.32%	-32.40%

May. 07	Transcript : AbCellera Biologics Inc., Q1 2024 Earnings Call, May 07, 2024
May. 07	AbCellera Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Benchmark Upgrades AbCellera Biologics to Buy From Hold, Price Target is $9	Feb. 22	MT
Stifel Lowers Price Target on AbCellera Biologics to $17 From $21, Maintains Buy Rating	Feb. 21	MT
KeyBanc Initiates AbCellera Biologics at Overweight With $6 Price Target, Cites 'Robust' Platform, 'Attractive' Valuation	Dec. 05	MT
Piper Sandler Assumes AbCellera Biologics at Overweight With $20 Price Target	23-10-13	MT
Benchmark Adjusts AbCellera Biologics' Price Target to $12 From $20, Keeps Buy Rating	23-08-31	MT
Goldman Sachs Adjusts AbCellera Biologics' Price Target to $24 From $27, Keeps Buy Rating	23-08-04	MT
Berenberg Bank Adjusts AbCellera Biologics Price Target to $34 From $38, Maintains Buy Rating	23-08-04	MT
Credit Suisse Lowers AbCellera Biologics' Price Target to $28 From $34, Keeps Outperform Rating	23-05-05	MT
Cowen Starts AbCellera Biologics at Outperform	23-02-28	MT
BMO Capital Cuts Price Target on AbCellera Biologics to $32 From $40, Maintains Outperform Rating	23-02-22	MT
Berenberg Bank Adjusts AbCellera Biologics' Price Target to $38 From $43, Maintains Buy Rating	23-02-22	MT
Prospect of Further Federal Reserve Interest Rate Increases Pressuring Exchange-Traded Funds, Equity Futures	23-01-24	MT
Fed Rate Outlook, China Optimism Lift Exchange-Traded Funds, Equity Futures Pre-Bell	23-01-20	MT
SVB Securities Adjusts Price Target on AbCellera Biologics to $18 From $20, Maintains Outperform Rating	23-01-06	MT
Goldman Sachs Initiates AbCellera Biologics at Buy With $30 Price Target	22-12-15	MT
Truist Securities Starts AbCellera Biologics at Buy With $29 Price Target	22-11-16	MT
SVB Securities Raises Price Target on AbCellera Biologics to $20 From $13, Maintains Outperform Rating	22-11-09	MT
Piper Sandler Trims Price Target on AbCellera Biologics to $21 From $22, Maintains Overweight Rating	22-11-01	MT
Credit Suisse Lowers AbCellera Biologics' PT to $34 from $40, Updates Model with Q2 Actuals, Adjusts Near-Term Program Projections; Keeps Outperform Rating	22-08-10	MT
Piper Sandler Adjusts Price Target on AbCellera Biologics to $22 From $21, Reiterates Overweight Rating	22-07-26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. AbCellera Biologics Inc.

Equities

ABCL

CA00288U1066

Analyst Reco.

Filters